Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

Who May Qualify: - Adult patients (≥18 years of age) - diagnosed by tissue sample (biopsy-confirmed) NSCLC with liver metastases - Eligible for immune checkpoint inhibitors per treating medical oncologist - Disease must be measurable per RECIST criteria - You should be able to carry out daily activities with 0 level of ability (ECOG 0) - 2 - your organs (liver, kidneys, etc.) are working well enough based on blood tests per protocol. - Allowable prior therapy includes adjuvant durvalumab, prior radiotherapy outside the upper abdomen. - Patients must be willing and able to sign an willing to sign a consent form form. - Participants of childbearing potential willing to undergo pregnancy test and use contraception per Appendix. Who Should NOT Join This Trial: - Liver tumor burden which cannot be targeted with SBRT per treating radiation oncologist - Presence of uncontrolled intercurrent illness or significant comorbidities precluding participation in a clinical study as determined by investigator - Diagnosis of underlying parenchymal end stage liver disease (cirrhosis) or biliary disease (primary biliary cirrhosis). - Other invasive malignancy active within 1 years, excluding in situ cancers - Presence of psychiatric or substance abuse disorders that would interfere with compliance or safety - Has a known history of active Bacillus Tuberculosis (TB), Hepatitis B or Hepatitis C infection - Has received a live (active) vaccine within 30 days of enrollment. - Active autoimmune conditions (where your immune system attacks your own body) that has required systemic treatment in the past 1 years aside from hormone replacement therapy (ie. thyroxine, insulin, or physiologic corticosteroid replacement therapy) - Baseline corticosteroid use (\>10 mg prednisone daily or equivalent) at study entry - Pregnancy or breast feeding Always talk to your doctor about whether this trial is right for you.